These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 38355548)

  • 21. Instigation of the epoch of nanovaccines in cancer immunotherapy.
    Shah S; Famta P; Tiwari V; Kotha AK; Kashikar R; Chougule MB; Chung YH; Steinmetz NF; Uddin M; Singh SB; Srivastava S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1870. PubMed ID: 36410742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
    Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
    Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
    Yip T; Qi X; Yan H; Chang Y
    ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
    Wang QT; Liu YX; Wang J; Wang H
    ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
    Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
    Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy.
    He X; Wang J; Tang Y; Chiang ST; Han T; Chen Q; Qian C; Shen X; Li R; Ai X
    Adv Healthc Mater; 2023 Sep; 12(23):e2300351. PubMed ID: 37289567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.
    Grimaudo MA
    Adv Exp Med Biol; 2021; 1295():303-315. PubMed ID: 33543465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
    Liu J; Zhang R; Xu ZP
    Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential of nanoparticle vaccines as a treatment for cancer.
    Urbanavicius D; Alvarez T; Such GK; Johnston APR; Mintern JD
    Mol Immunol; 2018 Jun; 98():2-7. PubMed ID: 29395251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
    Klippstein R; Pozo D
    Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanovaccines: An effective therapeutic approach for cancer therapy.
    Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
    Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanoparticle delivery systems in cancer vaccines.
    Krishnamachari Y; Geary SM; Lemke CD; Salem AK
    Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection.
    Xu F; Yuan Y; Wang Y; Yin Q
    Biomed Pharmacother; 2023 Feb; 158():114117. PubMed ID: 36528914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies.
    Shahgolzari M; Dianat-Moghadam H; Fiering S
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):1076-1085. PubMed ID: 34375725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanobiomaterial-based vaccination immunotherapy of cancer.
    Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
    Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy.
    Meng L; Teng Z; Yang S; Wang N; Guan Y; Chen X; Liu Y
    Nanoscale; 2023 Apr; 15(14):6432-6455. PubMed ID: 36916703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoadjuvants for cancer immunotherapy: A review of recent developments.
    Banstola A; Jeong JH; Yook S
    Acta Biomater; 2020 Sep; 114():16-30. PubMed ID: 32777293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.